[Management of neuroendocrine disorders in traumatic toxicosis using mielopid].
The object of the study was to determine the possibility of using myelopid in correction of the functional condition of the melatonin-opioid and the hypothalamo-hypophyseal-adrenal systems and of the activity of the neurohypophysis in traumatic toxicosis. It was demonstrated in rat experiments that in traumatic toxicosis myelopid modulates synthesis of neuropeptides (melatonin, corticoliberin) and their release into blood plasma. By reducing the blood plasma vasopressin content, myelopid promotes increase in the corticoliberin content in the hypothalamus and increase of 11-OCS biosynthesis in the adrenals. At the same time, the agent increases the melatonin content in the epiphysis cerebri of intact animals and in rats with traumatic toxicosis and reduces the content of leuenkephalin in blood plasma. The role of myelopid in correction of neuroendocrine disorders in traumatic toxicosis is discussed.
Samsonenko
R A
RA
El'skiĭ
V N
VN
Evtushenko
S K
SK
Titievskiĭ
A V
AV
D028341:Activins; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D004353:Drug Evaluation, Preclinical; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008550:Melatonin / Q000502:physiology; D009490:Neurosecretory Systems / Q000187:drug effects* / Q000503:physiopathology; D009842:Oligopeptides; D010455:Peptides / Q000627:therapeutic use*; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000503:physiopathology; D051381:Rats; D011957:Receptors, Opioid / Q000187:drug effects / Q000502:physiology; D012774:Shock, Traumatic / Q000188:drug therapy* / Q000503:physiopathology
D000276:Adjuvants, Immunologic; D009842:Oligopeptides; D010455:Peptides; D011957:Receptors, Opioid; C044147:activin B; D028341:Activins; C048617:myelopeptides; D008550:Melatonin
Korrektsiia mielopidom neĭroéndokrinnykh narusheniĭ pri travmaticheskom toksikoze.